Soligenix (NASDAQ:SNGX) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Soligenix (NASDAQ:SNGX) posted its earnings results on Friday. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.02, Zacks reports.

Soligenix Trading Down 4.9%

NASDAQ:SNGX traded down $0.02 during trading hours on Friday, reaching $0.29. 997,871 shares of the company were exchanged, compared to its average volume of 501,634. The stock’s 50-day moving average is $1.10 and its 200-day moving average is $1.28. The firm has a market cap of $3.02 million, a PE ratio of -0.08 and a beta of 1.31. Soligenix has a twelve month low of $0.29 and a twelve month high of $6.23.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Soligenix in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $6.00.

Hedge Funds Weigh In On Soligenix

Large investors have recently added to or reduced their stakes in the stock. XTX Topco Ltd purchased a new position in shares of Soligenix in the fourth quarter worth about $37,000. StoneX Group Inc. purchased a new position in shares of Soligenix in the fourth quarter worth about $50,000. Jane Street Group LLC purchased a new position in shares of Soligenix in the fourth quarter worth about $51,000. Banco BTG Pactual S.A. purchased a new position in shares of Soligenix in the third quarter worth about $54,000. Finally, Virtu Financial LLC purchased a new position in shares of Soligenix in the third quarter worth about $59,000. 3.60% of the stock is currently owned by institutional investors and hedge funds.

Soligenix Company Profile

Soligenix, Inc is a clinical?stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small?molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions.